Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
  • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
  • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
  • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
  • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines

Definitions

• the present invention relates to a therapeutic agent for a corneal disease, and more particularly, it relates to a therapeutic agent for a corneal disease applicable to a disorder in the anterior epithelium of cornea, particularly in a formulation of ophthalmic solutions.
• Disorder in the anterior epithelium of cornea can be classified roughly into 4 types, that is, (1) one caused by an inflammation such as infection, (2) hereditary disease, (3) exogenous physical injury and chemical injury caused by chemicals, and (4) nutritional disorder.
• corneal diseases there is a tendency for corneal diseases to increase in recent years due to physical injury accompanied by lacrimal hyposecretion (so-called dry-eye) with the spread of personal computers and contact lens, and those caused by pollinosis, particularly disorder in the anterior epithelium; thus, a drug effective to corneal diseases or disorders in the anterior epithelium of cornea has been demanded.
• the present inventors have searched for a variety of drugs which have a therapeutic effect on corneal diseases and found that irsogladine maleate, which has widely been used as a medicament for internal application in treatment of gastric ulcer or gastric mucosal lesion, has an excellent therapeutic effect on corneal diseases.
• the invention was thus completed.
• the present invention provides a therapeutic agent for a corneal disease which comprises irsogladine or a salt thereof as an active ingredient.
• the present invention also provides a therapeutic agent for a corneal disease as mentioned above which is in a formulation of ophthalmic solutions and which is particularly applicable to disorders in the anterior epithelium of cornea.
• the therapeutic agent of a corneal disease of the present invention has an effect of significantly promoting a cure of corneal diseases, particularly cure of disorders in the anterior epithelium of cornea.
• the corneal disease in the present invention indicates conditions of injured cornea caused by various factors, specifically including keratitis caused by physical/chemical irritation, allergy, bacteria/fungi/virus infections, etc., as well as corneal ulcer, abrasion of the anterior epithelium of cornea (corneal erosion), edema of the anterior epithelium of cornea, corneal burn, corneal corrosion by chemicals, dry-eye, and the like.
• the therapeutic agent for a corneal disease of the invention comprises irsogladine or a salt thereof as an active ingredient.
• Irsoglandine and salts thereof as active ingredients are drugs having an anti-ulcer effect, one of which irsogladine maleate (2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine maleate) has widely been used as an internal formulation in treatment of gastric ulcer or gastric mucosal lesion. It has not yet been known, however, that the ingredient is effective as a therapeutic agent for a corneal disease, particularly in treatment of a disorder of the anterior epithelium of cornea.
• the content of irsogladine or salt thereof is usually, for example, when irsogladine maleate is used in a liquid preparation such as ophthalmic solution or eyewash, preferably 0.01 w/v % to 3 w/v %, more preferably 0.05 w/v % to 1 w/v %, and most particularly 0.1 w/v % to 0.5 w/v %.
• the therapeutic agent for a corneal disease of the present invention can be formulated into an optional formulation which can be applied to the cornea, and it is desired to usually provide as a form of ophthalmic solution, eyewash, ophthalmic ointment, and the like, in particular as a form of ophthalmic solution.
• the therapeutic agent for a corneal disease of the present invention is provided as an ophthalmic solution
• the active ingredient irsogladine or a salt thereof a variety of optional ingredients including buffer, tonicity agent, solubilizer, surfactant, stabilizer, preservative, pH adjuster, and the like.
• buffer such as potassium dihydrogen phosphate, sodium hydrogen phosphate, boric acid, sodium borate, sodium citrate, sodium acetate, monoethanolamine, trometamol, and the like; tonicity agent such as sodium chloride, potassium chloride, glycerin, glucose, and the like; solubilizer such as ethanol, castor oil, and the like; surfactant such as polysorbate 80, polyoxyethylene hardened castor oil, and the like; stabilizer such as sodium ethylenediaminetetraacetate and the like; preservative such as benzalkonium chloride, benzethonium chloride, chlorobutanol, benzyl alcohol, and the like, and pH adjuster such as hydrochloric acid, sodium hydroxide, and the like.
• buffer such as potassium dihydrogen phosphate, sodium hydrogen phosphate, boric acid, sodium borate, sodium citrate, sodium acetate, monoethanolamine, trometamol, and the like
• tonicity agent such as sodium chloride, potassium chlor
• the therapeutic agent for a corneal disease of the present invention can be simultaneously used with another type of therapeutic ingredients for a corneal disease of which the action mechanism is considered to be different in order to enhance additively or synergistically the therapeutic effect.
• the another type of therapeutic ingredients for a corneal disease includes, for example, hyaluronic acid or its salt or chondroitin sulfate or its salt. Those ingredients may be combined with irsogladine or a salt thereof, or may be separately formulated into a single formulation for treatment of a corneal disease so as to use concomitantly.
• the therapeutic agent for a corneal disease thus obtained may be applied appropriately to the cornea depending on the type or severity of a corneal disease.
• a dose of about 0.01 to 0.1 mL for one eye may be administered 3 to 6 times per day.
• the therapeutic agent for a corneal disease of the invention is not limited by Examples described below, and of course it may be modified in various ways within the scope of the invention as far as the modification does not depart from the gist of the invention.
• Irsogladine maleate was dissolved in ethanol, and polysorbate 80 was added to the solution. Then, physiological saline was added to the mixture to obtain 100 mL of a therapeutic agent for a corneal disease as an ophthalmic solution.
• Irsogladine maleate was dissolved in ethanol, and polysorbate 80 was added to the solution. Then, physiological saline was added to the mixture to obtain 100 mL of a therapeutic agent for a corneal disease as an ophthalmic solution.
• Irsogladine maleate was mixed with castor oil in a conventional manner to obtain a therapeutic agent for a corneal disease as an oily-based ophthalmic solution.
• Irsogladine maleate was added to a mixture of liquid paraffin and vaseline, and the mixture thus obtained was admixed with stirring in a conventional manner to obtain a therapeutic agent for a corneal disease as an ophthalmic ointment.
• a matured white rabbit (about 2 kg of body weight) was anesthetized with pentobarbital sodium (0.4 mL/kg) injected into auricular vein; the eyelid was widely opened with an eye speculum, to which 30 ⁇ L of benoxil ophthalmic solution was applied to anesthetize the eye surface. Then, a membrane filter (6 mm in diameter) moistened with n-heptanol was placed at the center of rabbit's cornea for one minute to yield corneal injury. After the filter was removed, the eye was washed well with sterilized physiological saline.
• Example 2 At three, four and five hours after formation of the wound, 100 ⁇ L of the therapeutic agents for corneal disease (ophthalmic solution) prepared in Example 1 and Example 2, respectively, were applied to the eye.
• physiological saline containing 2% ethanol and 2% polysorbate 80 was used as a control for Example 1
• physiological saline containing 5% ethanol and 2% polysorbate 80 was used as a control for Example 2.
• 1% aqueous fluorescein solution 50 ⁇ L was applied to the eye for staining. After that, excess fluorescein was washed out with sterilized physiological saline. Subsequently, the cornea was photographed with a digital camera fitted to a photo-slit lamp to observe the status of cure of the wound.
• the stained area was measured using a image processing software with a label width (5 mm) of eye speculum as a standard, and this was regarded as a wound area. From those results, the cure rate was calculated according to the following formula.
• Cure rate (%) [1 ⁇ ( S B /S A )] ⁇ 100
• Table 1 shows the test results in the therapeutic agent-1 for a corneal disease
• Table 2 shows the test results in the therapeutic agent-2 for a corneal disease, respectively.
• the therapeutic agent for a corneal disease in the present invention has a potent curative effect to a disorder in the anterior epithelium of cornea.
• the pharmaceutical preparation of the present invention comprising irsogladine maleate as an active ingredient has an effect significantly promoting a cure of a corneal disease, particularly, a cure of a disorder in the anterior epithelium of cornea.
• the pharmaceutical preparation accordingly, is effective as a novel therapeutic agent for a corneal disease.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Ophthalmology & Optometry (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=37307968

Family Applications (2)

Family Applications After (1)

Country Status (6)

Cited By (3)

Citations (1)

Family Cites Families (5)

• 2005
  • 2005-04-27 JP JP2005129450A patent/JP4778262B2/ja not_active Expired - Fee Related
• 2006
  • 2006-04-27 PL PL06745731.7T patent/PL1876175T3/pl unknown
  • 2006-04-27 ES ES06745731.7T patent/ES2581247T3/es active Active
  • 2006-04-27 US US11/912,899 patent/US20090030001A1/en not_active Abandoned
  • 2006-04-27 WO PCT/JP2006/308803 patent/WO2006118170A1/ja active Application Filing
  • 2006-04-27 EP EP06745731.7A patent/EP1876175B1/en not_active Not-in-force
• 2010
  • 2010-01-12 US US12/685,860 patent/US8268824B2/en active Active

Patent Citations (1)

Also Published As

Similar Documents

Legal Events